Eton Pharmaceuticals, Inc. Deferred Revenue Recognized
Eton Pharmaceuticals, Inc. (ETON) reported Deferred Revenue Recognized of $17.00 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2022-11-10
- 2022-09-30: Contract with Customer, Liability, Revenue Recognized 9 month $17.00M.
| Period end | Contract with Customer, Liability, Revenue Recognized 9 month |
|---|---|
| 2022-09-30 | $17.00M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |